Tumor vaccine

Abstract

The invention relates to the fields of medicine, immunology, and oncology. More specifically, the invention relates to methods and compositions for inducing an immune response against a tumor in an animal subject. The invention provides that a lung cancer cell or other tumor cells, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, and method for stimulating an immune response to a tumor with the tumor cell so genetically modified. The invention additionally provides a method of inhibiting a tumor, including a cancer such as lung cancer, by administering an allogeneic tumor cell, for example a cancer tumor cell such as a lung cancer tumor cell, genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen.

1 . A method of producing a protective immune response in a human subject comprising administering to the subject an effective amount of lung cancer cells transfected with a eukaryotic expression vector derived from the bovine papilloma virus comprising a nucleic acid encoding CD80 (B7.1) and with a eukaryotic expression vector derived from the bovine papilloma virus comprising a nucleic acid encoding an HLA antigen. 
     
     
         2 . The method of  claim 1 , wherein the eukaryotic expression vector comprises a nucleic acid encoding a mouse metallothionein-I promoter (MTI). 
     
     
         3 . The method of  claim 1 , wherein the eukaryotic expression vector comprises a nucleic acid encoding a G418 resistance gene or histidinol resistance gene. 
     
     
         4 . The method of  claim 1 , wherein the HLA antigen is selected from HLA A1, HLA A2, HLA A3 and HLA A27. 
     
     
         5 . The method of  claim 1 , wherein the lung cancer cell is an adenocarcinoma. 
     
     
         6 . The method of  claim 2 , wherein the HLA antigen is selected from HLA A1, HLA A2, HLA A3 and HLA A27. 
     
     
         7 . The method of  claim 2 , wherein the lung cancer cell is an adenocarcinoma. 
     
     
         8 . The method of  claim 1 , wherein the lung cancer cells are administered more than once. 
     
     
         9 . A method of producing a protective immune response in a human subject comprising administering to the subject an effective amount of lung cancer cells transfected with a eukaryotic expression vector derived from the bovine papilloma virus comprising a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen. 
     
     
         10 . The method of  claim 9 , wherein the eukaryotic expression vector comprises a nucleic acid encoding a mouse metallothionein-I promoter (MTI) and a nucleic acid encoding a cytomegalovirus (CMV) promoter. 
     
     
         11 . The method of  claim 9 , wherein the eukaryotic expression vector comprises a nucleic acid encoding a G418 resistance gene or histidinol resistance gene. 
     
     
         12 . The method of  claim 9 , wherein the HLA antigen is selected from HLA A1, HLA A2, HLA A3 and HLA A27. 
     
     
         13 . The method of  claim 9 , wherein the lung cancer cell is an adenocarcinoma. 
     
     
         14 . The method of  claim 10 , wherein the HLA antigen is selected from HLA A1, HLA A2, HLA A3 and HLA A27. 
     
     
         15 . The method of  claim 10 , wherein the lung cancer cell is an adenocarcinoma. 
     
     
         16 . The method of  claim 9 , wherein the lung cancer cells are administered more than once. 
     
     
         17 . A population of lung cancer cells genetically modified to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, wherein at least at least 70% of the cells co-express CD80 (B7.1) and an HLA antigen. 
     
     
         18 . The population of lung cancer cells of  claim 17 , wherein the HLA antigen is selected from HLA A1, HLA A2, HLA A3 and HLA A27. 
     
     
         19 . The population of lung cancer cells of  claim 17 , wherein the lung cancer cell is an adenocarcinoma. 
     
     
         20 . A method of manufacturing a vaccine against lung cancer comprising genetically modifying a population of lung cancer cells to express a nucleic acid encoding CD80 (B7.1) and a nucleic acid encoding an HLA antigen, wherein at least at least 70% of the cells co-express CD80 (B7.1) and an HLA antigen. 
     
     
         21 . The method of  claim 20 , wherein the HLA antigen is selected from HLA A1, HLA A2, HLA A3 and HLA A27. 
     
     
         22 . The method of  claim 20 , wherein the lung cancer cell is an adenocarcinoma.